Guwahati: Drug major Lupin announced the launch of its Favipiravir drug on Wednesday, under the brand name 'Covihalt' for the treatment of patients with mild to moderate COVID-19 symptoms, at Rs 49 per tablet in India.
Lupin said in a regulatory filing that Favipiravir has received approval from the Drug Controller General of India (DCGI) for emergency use.
The Covid-19 drug Covihalt dosage strength has been developed keeping in mind the convenience of administration, the filing stated, adding that the drug is available as 200 mg tablets in the form of a strip of 10 tablets.
Rajeev Sibal, Lupin President - India Region Formulations (IRF), said the company believes that it can use its expertise in handling widespread community diseases like tuberculosis to proactively reach patients across India and ensure access to Covihalt through its strong distribution network.
On August 4, Sun Pharmaceutical Industries had launched Favipiravir under the brand name ''FluGuard'' for the treatment of mild to moderate cases of COVID-19, at Rs 35 per tablet in India.
After the announcement of the launch, the sGuwahatihares of Lupin were trading 0.32 percent higher at Rs 943.70 apiece on BSE.